公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
2021 | Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies | Berghoff A.S.; Sessa C.; CHIH-HSIN YANG ; Tsourti Z.; Tsang J.; Tabernero J.; Peters S.; Linardou H.; Letsch A.; Haanen J.; Garralda E.; Garassino M.C.; Furness A.J.S.; Felip E.; Dimopoulou G.; Dafni U.; Choo S.P.; Banerjee S.; Bajpai J.; Adjei A.A.; Garrido P. | ESMO Open | 10 | 5 | |
2022 | Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC | Wu, Yi-Long; Lu, Shun; CHIH-HSIN YANG ; Zhou, Jianying; Seto, Takashi; Ahn, Myung-Ju; Su, Wu-Chou; Yamamoto, Noboru; Kim, Dong-Wan; Paolini, Jolanda; Usari, Tiziana; Iadeluca, Laura; Wilner, Keith D; Goto, Koichi | JTO clinical and research reports | 4 | 0 | |
2008 | First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; CHIH-HSIN YANG ; SHANG-GIN WU ; Chiu Y.-H.; Gow C.-H.; YEUN-CHUNG CHANG ; Hsu Y.-C.; Wei P.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 69 | 62 | |
2019 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials | Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG | Lung Cancer | 26 | 19 | |
2019 | First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting | Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 23 | 24 | |
2016 | First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases | Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG | Journal of Thoracic Oncology | 289 | 259 | |
2019 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression | Schuler M; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. | Journal of Cancer Research and Clinical Oncology | 29 | 27 | |
2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 15 | 16 | |
2016 | First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial | Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG | Clinical Lung Cancer | 12 | 13 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2009 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG ; Liao M; Lim W.-T; Goldstraw P; Mok T.S. | The Lancet Oncology | 23 | 20 | |
2002 | Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment [8] | CHIA-YU CHU ; CHIH-HSIN YANG ; HSIEN-CHING CHIU | Acta Dermato-Venereologica | 6 | 2 | |
2000 | Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel | CHIA-YU CHU ; CHIH-HSIN YANG ; Yang C.-Y.; Hsiao G.-H.; HSIEN-CHING CHIU | British Journal of Dermatology | 64 | 45 | |
2008 | Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma | SHANG-GIN WU ; Gow C.-H.; CHONG-JEN YU ; YIH-LEONG CHANG ; CHIH-HSIN YANG ; Hsu Y.-C.; JIN-YUAN SHIH ; Lee Y.-C.; PAN-CHYR YANG | European Respiratory Journal | 109 | 95 | |
2012 | Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study | BIN-CHI LIAO ; CHIH-HSIN YANG | Translational Lung Cancer Research | 0 | 0 | |
2006 | Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study | Chang A; Parikh P; Thongprasert S; Tan E.H; Perng R.-P; Ganzon D; CHIH-HSIN YANG ; Tsao C.-J; Watkins C; Botwood N; Thatcher N. | Journal of Thoracic Oncology | 186 | 153 | |
2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
2009 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG ; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. | New England Journal of Medicine | 7325 | 6479 | |
2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |